# EDGAR Filing Document

**Accession Number:** 0001426753
**File Stem:** 0001213900-26-032597
**Filing Date:** 2026-3
**Character Count:** 5717
**Document Hash:** a4d7958515696ecba10704034f181c64
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-032597.hdr.sgml**: 20260323

**ACCESSION NUMBER**: 0001213900-26-032597

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260323

**FILED AS OF DATE**: 20260323

**DATE AS OF CHANGE**: 20260323

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** DAVIDI ISHAY
- **CENTRAL INDEX KEY:** 0001426753

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-35948
- **FILM NUMBER:** 26779863

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** C/O NASCHITZ, BRANDES, AMIR & CO.
- **STREET 2:** 5 TUVAL STREET
- **CITY:** TEL AVIV
- **PROVINCE COUNTRY:** L3
- **ZIP:** 6789717
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** KAMADA LTD
- **CENTRAL INDEX KEY:** 0001567529
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** L3
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 2 HOLTZMAN ST., SCIENCE PARK
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7670402
- **BUSINESS PHONE:** 97289406472

**MAIL ADDRESS:**
- **STREET 1:** 2 HOLTZMAN ST., SCIENCE PARK
- **CITY:** REHOVOT
- **STATE:** L3
- **ZIP:** 7670402

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>DAVIDI ISHAY<br><sub>(Last) (First) (Middle)</sub><br>94 YIGAL ALON ST., ALON TOWER 2.<br><sub>(Street)</sub><br>TEL AVIV, ISRAEL 6789139<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>KAMADA LTD [ KMDA ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-03-23 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Ordinary Shares | 22084287 | I | Held through controlled entities<sup>(1)</sup> |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Options to purchase Ordinary Shares<sup>(2)</sup> | 2021-03-25 | 2026-09-25 | Ordinary Shares | 6625 | 7.52<sup>(3)</sup> | D |  |
| Options to purchase Ordinary Shares<sup>(2)</sup> | 2022-03-25 | 2026-09-25 | Ordinary Shares | 6625 | 7.52<sup>(3)</sup> | D |  |
| Options to purchase Ordinary Shares<sup>(2)</sup> | 2023-03-25 | 2026-09-25 | Ordinary Shares | 6625 | 7.52<sup>(3)</sup> | D |  |
| Options to purchase Ordinary Shares<sup>(2)</sup> | 2023-12-22 | 2029-06-22 | Ordinary Shares | 7500 | 6.15<sup>(3)</sup> | D |  |
| Options to purchase Ordinary Shares<sup>(2)</sup> | 2024-03-25 | 2026-09-25 | Ordinary Shares | 6625 | 7.52<sup>(3)</sup> | D |  |
| Options to purchase Ordinary Shares<sup>(2)</sup> | 2024-12-22 | 2029-06-22 | Ordinary Shares | 7500 | 6.15<sup>(3)</sup> | D |  |
| Options to purchase Ordinary Shares<sup>(2)</sup> | 2025-12-22 | 2029-06-22 | Ordinary Shares | 7500 | 6.15<sup>(3)</sup> | D |  |
| Options to purchase Ordinary Shares<sup>(2)</sup> | 2026-12-22 | 2029-06-22 | Ordinary Shares | 7500 | 6.15<sup>(3)</sup> | D |  |

---

### Footnotes:

(1) FIMI Opportunity Fund 6, L.P., FIMI Israel Opportunity Fund 6, Limited Partnership, FIMI Opportunity 7, L.P. and FIMI Israel Opportunity Fund 7, Limited Partnership

(2) These options to purchase ordinary shares are exercisable using a net-exercise method

(3) All exercise prices presented in U.S. dollars represent a convenience translation from NIS based on the representative exchange rate of the Bank of Israel as of March 13, 2026.

**Signature:** /s/ Ishay Davidi  
**Date:** 2026-03-23

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**